OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Vogel on the Utility of Frontline Lenvatinib or Sorafenib in HCC

September 4th 2021

Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.

Dr. Singal on the Results of a Mailed Outreach Strategy for Surveillance Utilization in HCC

September 4th 2021

Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.

Dr. Mogal on the Incidence and Prognosis of Peritoneal Carcinomatosis in CRC

September 3rd 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the incidence and prognosis of peritoneal carcinomatosis in colorectal cancer.

Dr. Dietrich on Future Research Directions in Lung Cancer

September 3rd 2021

Martin Dietrich, MD, PhD, discusses future research directions for the treatment of patients with lung cancer.

Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma

September 3rd 2021

Frits van Rhee, MD, PhD, discusses future research directions with CAR T-cell therapy for the treatment of patients with multiple myeloma.

Dr. Castillo on the Integration of BTK Inhibitors in Waldenström

September 3rd 2021

Jorge J. Castillo, MD, discusses the integration of BTK inhibitors in Waldenström macroglobulinemia.

Dr. Herrera on the Utility of CAR T-Cell Therapy in Hematologic Cancers

September 3rd 2021

Alex Herrera, MD, discusses the utility of CAR T cells in patients with hematologic cancers.

Dr. Harris on IMbrave150 Results With Atezolizumab/Bevacizumab in HCC

September 3rd 2021

William P. Harris, MD, discusses updated data from the phase 3 IMbrave150 study in hepatocellular carcinoma.

Dr. Ailawadhi on Patient Considerations for BTK Inhibitors in Waldenström Macroglobulinemia

September 3rd 2021

Sikander Ailawadhi, MD, discusses patient considerations for BTK inhibitors in Waldenström macroglobulinemia.

Dr. Cohen on Tailoring Treatment to Individual Subtypes in CRC

September 2nd 2021

Stacey A. Cohen, MD, discusses tailoring treatment approaches to individual subtypes in colorectal cancer.

Dr. Chiorean on the Role of Molecular Testing in Pancreatic Cancer

September 2nd 2021

E. Gabriela Chiorean, MD, discusses the role of molecular testing in pancreatic cancer.

Dr. Rampal on the Importance of Genomic Testing in Myelofibrosis

September 2nd 2021

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.

Dr. Patil on ADAURA Data with Osimertinib in NSCLC

September 2nd 2021

Pradnya D. Patil, MD, FACP, discusses data from the phase 3 ADAURA trial in patients with EGFR-mutated non–small cell lung cancer.

Dr. Hurvitz on Outcomes With Sacituzumab Govitecan in TNBC

September 1st 2021

Sara A. Hurvitz, MD, discusses outcomes with sacituzumab govitecan-hziy in patients with metastatic triple-negative breast cancer.

Dr. Garg on the Need for Novel Imaging Techniques in nmCRPC

September 1st 2021

Natasha Garg, DO, discusses the utility of novel imaging techniques in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Wang on the Final Results of the ACE-LY-004 Trial in MCL

September 1st 2021

Michael Wang, MD, discusses the use of acalabrutinib in the phase 2 ACE-LY-004 trial in mantle cell lymphoma.

Dr. Stevenson on the Importance of Early Screening in Lung Cancer

September 1st 2021

James Stevenson, MD, discusses the importance of early screening in lung cancer.

Dr. Riedell on the Importance of Identifying Early Relapse High-Risk MCL

September 1st 2021

Peter Riedell, MD, discusses the importance of identifying early relapse in patients with high-risk mantle cell lymphoma.

Dr. Atallah on the Prognostic Role of Undetectable MRD in CLL

August 31st 2021

Ehab L. Atallah, MD, discusses the prognostic role of undetectable minimal residual disease in chronic lymphocytic leukemia.

Dr. Murthy on the Potential Benefits of Treatment De-Escalation in Ph+ B-ALL

August 31st 2021

Guru Subramanian Guru Murthy, MD, MS, discusses the potential benefits of treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.